Elisa Agostinetto: Immunotherapy has reshaped the cancer treatment paradigm
Elisa Agostinetto shared on X:
“Immunotherapy has reshaped cancer treatment paradigm, but we still need biomarkers for patient selection.
This paper on Nature Cancer introduces an approach using multi-omics data and machine learning to improve patient selection for IO.”
Source: Elisa Agostinetto/X
Enhanced precision in immunotherapy.
Authors: Erik N. Bergstrom and Ludmil B. Alexandrov.
Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care.
Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023